New hope for advanced breast cancer: early trial of oral drug LY3484356 begins

NCT ID NCT05509790

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or control the disease. Participation can last up to 28 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3484356 (an oral drug)
What this could lead to: If successful, this could lead to a new oral treatment option for Chinese patients with advanced ER+/HER2- breast cancer.
What could go wrong: This is a very early phase 1 study with only 17 participants, so results may not apply broadly. The drug may not prove effective or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 201315, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
The Third Hospital of Nanchang

Nanchang, Jiangxi, 330025, China
Wannan Medical College Yijishan Hospital

Wuhu, Anhui, 241001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.